Krystal Biotech, Inc. KRYS Accounts Receivable, Allowance for Credit Loss
Accounts Receivable, Allowance for Credit Loss at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivable.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s accounts receivable, allowance for credit loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s accounts receivable, allowance for credit loss?
- Krystal Biotech, Inc. (KRYS) reported accounts receivable, allowance for credit loss of $81.34M in Q1 2026.
- How has Krystal Biotech, Inc.'s accounts receivable, allowance for credit loss changed year-over-year?
- Krystal Biotech, Inc.'s accounts receivable, allowance for credit loss increased by 55.6% year-over-year, from $52.28M to $81.34M.
- What is the long-term trend for Krystal Biotech, Inc.'s accounts receivable, allowance for credit loss?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s accounts receivable, allowance for credit loss has grown at a 209.4% compound annual growth rate (CAGR), from $7.11M to $68.12M.